SEC Form 4 · accession 0001493152-18-008235
GALECTIN THERAPEUTICS INC · GALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Jun 1, 2018
Accepted (ET)
Jun 5, 2018 · 4:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001133416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 1, 2018 | S | 41,907 | $5.12 | D | 3,161,693 | I | see footnote |
| Common StockF1 | Jun 4, 2018 | S | 8,093 | $5.13 | D | 3,119,786 | I | see footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F110X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. 10X Capital Management, LLC disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.